The roles of histone deacetylases and their inhibitors in cancer therapy

G Li, Y Tian, WG Zhu - Frontiers in cell and developmental biology, 2020 - frontiersin.org
Genetic mutations and abnormal gene regulation are key mechanisms underlying
tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores …

Histone deacetylase inhibitors: molecular mechanisms of action

WS Xu, RB Parmigiani, PA Marks - Oncogene, 2007 - nature.com
This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors
(HDACi), a group of recently discovered 'targeted'anticancer agents. There are 18 HDACs …

Histone deacetylase inhibitors: Potential in cancer therapy

PA Marks, WS Xu - Journal of cellular biochemistry, 2009 - Wiley Online Library
The role of histone deacetylases (HDAC) and the potential of these enzymes as therapeutic
targets for cancer, neurodegenerative diseases and a number of other disorders is an area …

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

K Keller, M Jung - Epigenetic Therapy of Cancer: Preclinical Models and …, 2013 - Springer
Histone deacetylases are key enzymes of epigenetic regulation and are therefore involved
in crucial cellular events like transcription, differentiation, apoptosis and cell division. The …

Stem cell quiescence

L Li, R Bhatia - Clinical cancer research, 2011 - AACR
Adult stem cells are maintained in a quiescent state but are able to exit quiescence and
rapidly expand and differentiate in response to stress. The quiescent state appears to be …

Cancer epigenetics

PW Laird - Human molecular genetics, 2005 - academic.oup.com
The field of cancer epigenetics is evolving rapidly on several fronts. Advances in our
understanding of chromatin structure, histone modification, transcriptional activity and DNA …

[HTML][HTML] Trials with 'epigenetic'drugs: an update

A Nebbioso, V Carafa, R Benedetti, L Altucci - Molecular oncology, 2012 - Elsevier
Epigenetic inactivation of pivotal genes involved in correct cell growth is a hallmark of
human pathologies, in particular cancer. These epigenetic mechanisms, including crosstalk …

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

PA Marks - Expert opinion on investigational drugs, 2010 - Taylor & Francis
Importance of the field: Histone deacetylase (HDAC) inhibitors are being developed as a
new, targeted class of anticancer drugs. Area covered in this review: This review focuses on …

Teratogenic mechanisms of medical drugs

MMHJ Van Gelder, IALM Van Rooij… - Human reproduction …, 2010 - academic.oup.com
BACKGROUND Although prescription drug use is common during pregnancy, the human
teratogenic risks are undetermined for more than 90% of drug treatments approved in the …

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate

B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - Cancer cell, 2010 - cell.com
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …